Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Is the 4DMedical (ASX: 4DX) share price pop justified?

Shares in 4DMedical Limited (ASX: 4DX) are up over 47% off the back of some recent positive announcements. Is it too late to buy shares?

The 4DMedical Limited (ASX: 4DX) share price is up over 47% off the back of some recent positive announcements in recent times. Is it too late to buy 4DX shares?

Source: Rask Media. Click here to view the chart.

What does 4D Medical do?

4DMedical is a health technology SaaS business that operates in both Australia and the US. The company’s proprietary XV technology works by converting sequences of X-ray images into four-dimensional quantitative data by using patented mathematical models and algorithms.

Those words don’t make a lot of sense to me, but the technology aims to improve patient experiences and outcomes by allowing doctors to make better-informed decisions with earlier intervention.

What I like about this company

The area of medical technology is exciting and solves important issues that will help the quality of people’s lives. From this point alone, it would be great to see this company succeed and commercialise its product. 4D’s diagnostics aims to replace old technology such as X-ray and CT scans, which according to 4D are out-of-date and not fit for purpose anymore.

No initial capital expenditure is required by hospitals that wish to use 4D’s products due to the initial software integration being paid upfront by 4D. Hospitals can still use their existing imaging hardware and software, but 4D is able to integrate its technology into these older systems.

An attractive feature of 4D is the payment model. 4D charges a fee on a “per scan” basis, charging US$175 per test using the XV technology. The capital-light sales model that leverages existing infrastructure hopes to deliver a 90% gross margin.

Some concerns I hold

Like many other companies in medical technology, the initial research and approval stage is only one element of the overall business lifecycle. The XV product still needs to be commercialised on a large scale and distributed through a sales team. 4D states that it already has established relationships and plans to leverage this, but this is easier said than done.

I compare 4D Medical to Alcidion Group Ltd (ASX: ALC) which is also a SaaS provider in health monitoring. Alcidion also offers a fantastic product that solves real problems but is at the mercy of often underfunded hospitals using other alternatives on long-term contracts. 4D could be different, but it may not shoot the lights out in the short-term.

Taking a brief look at 4D’s financials, the company is still running at a loss due to it going through an approval/growth stage. This makes the valuation tricky as you can’t run a discounted cash flow model if you were to use this method.

It’s too early for management to provide any sort of earnings estimates or guidance, so using any sort of multiple is also out of the question.

At this point, it’s really just the market attributing a value that is purely based on big expectations. Only time will tell if future cash flows can justify the current share price.

Final thoughts

I would personally like to see at least a short length of demonstrated profitability, as I do notice AUD$17 million in borrowings on the balance sheet. Right now, I’d prefer a company with a longer track record such as Catapult Group International Ltd (ASX: CAT)

I also highly recommend that you watch this podcast with Rask Australia founder and analyst, Owen Raszkiewicz, and Strawman founder and investor, Andrew Page, if you’d like some further insight into Catapult.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Patrick owns shares in Alcidion Group Ltd.
Skip to content